Fri, Aug 22, 2014, 9:48 AM EDT - U.S. Markets close in 6 hrs 12 mins


% | $
Quotes you view appear here for quick access.

Endocyte, Inc. (ECYT) Message Board

  • chirag_487a chirag_487a Mar 24, 2014 2:04 PM Flag

    Red Acre writes before AF can strike

    TARGET Lung Cancer trial succeeds

    On Friday ECYT also reported that the phase 2 TARGET trial on vintafolide in FR100% non-small cell lung cancer patients met its primary endpoint. The combination of vintafoldie plus docetaxel showed a progression free survival hazard ratio of 0.75 with a p-value of 0.0696 using a 1-sided test.

    Note, a p-value 0.0696 is greater than 0.05 - so how does ECYT consider this a success? The pre-specified significance criteria according to the trial's statistical analysis plan was p

6.26-0.05(-0.79%)9:45 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.